DUBLIN--(BUSINESS WIRE)--The "Caspase 3 - Pipeline Review ... mechanism of action (MoA), route of administration (RoA) and molecule type. Reasons to buy Companies Mentioned Scope Key Topics ...

BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). Originator ...

AVT05 is a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions.